- Conditions
- Diabetes Mellitus, Type 1
- Interventions
- Gan & Lee Insulin Glargine Injection, Lantus®
- Biological
- Lead sponsor
- Gan and Lee Pharmaceuticals, USA
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 576 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 50
- States / cities
- Birmingham, Alabama • Fresno, California • Newport Beach, California + 41 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 304
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Insulin glargine/Lixisenatide, Insulin glargine (HOE901), Background therapy
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 241 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 85
- States / cities
- Montgomery, Alabama • Little Rock, Arkansas • Anaheim, California + 63 more
- Conditions
- Type 1 Diabetes
- Interventions
- Pramlintide, Exenatide, Insulin
- Drug
- Lead sponsor
- Albert Einstein College of Medicine
- Other
- Eligibility
- 12 Years to 21 Years
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2016
- U.S. locations
- 1
- States / cities
- The Bronx, New York
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- Insulin glargine (HOE901), Neutral Protamine Hagedorn (NPH) insulin, Insulin lispro
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 1 Year to 6 Years
- Enrollment
- 125 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 8
- States / cities
- Sacramento, California • San Diego, California • Greenwood Village, Colorado + 5 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- LY3209590, Insulin Glargine
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 70 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018
- U.S. locations
- 2
- States / cities
- South Miami, Florida • High Point, North Carolina
- Conditions
- Diabetes, Diabetes Mellitus, Type 2
- Interventions
- insulin degludec/liraglutide, insulin glargine
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 557 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 31
- States / cities
- Fresno, California • Los Alamitos, California • Palm Springs, California + 26 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Glimepiride, Metformin, Pioglitazone, Acarbose, Linagliptin, Sitagliptin, Liraglutide, Insulin Glargine, Exenatide once weekly (QW), Exenatide twice daily (BID)
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 65 Years and older
- Enrollment
- 192 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 16
- States / cities
- Miami, Florida • New Port Richey, Florida • Orlando, Florida + 12 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Glargine, LY2605541
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,538 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 66
- States / cities
- Anniston, Alabama • Mobile, Alabama • Chandler, Arizona + 63 more
- Conditions
- Diabetic Ketoacidosis
- Interventions
- insulin glargine+ glulisine, NPH + Regular insulin
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 74 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 2
- States / cities
- Atlanta, Georgia • Minneapolis, Minnesota
- Conditions
- Diabetes Mellitus Type 2
- Interventions
- insulin glargine, metformin, taspoglutide
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 1,072 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 74
- States / cities
- Phoenix, Arizona • Searcy, Arkansas • Concord, California + 63 more
- Conditions
- Gestational Diabetes Mellitus, Pregnancy in Diabetic, Pregnancy, High Risk
- Interventions
- Patient-led Insulin (intervention group), Provider-led Insulin (standard care)
- Drug
- Lead sponsor
- Ohio State University
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- LY2963016, Lantus, OAMs
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 759 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 28
- States / cities
- Montgomery, Alabama • Brooksville, Florida • Fort Lauderdale, Florida + 25 more
- Conditions
- Type 1 Diabetes
- Interventions
- Pramlintide, Glargine, Lispro, Aspart
- Drug
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 12 Years to 70 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- LY2963016, LANTUS®, Oral Antihyperglycemic Medication
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 493 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 10
- States / cities
- Miami, Florida • New Port Richey, Florida • Smyrna, Georgia + 7 more
- Conditions
- Type 2 Diabetes, Renal Insufficiency
- Interventions
- 0.5 units/kg daily insulin, 0.25 units/kg daily insulin
- Drug
- Lead sponsor
- Loyola University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 114 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 3
- States / cities
- Chicago, Illinois • Maywood, Illinois
- Conditions
- Type 2 Diabetes
- Interventions
- Lixisenatide (AVE0010), Insulin glulisine QD, Insulin glulisine TID, Insulin Glargine (Mandatory background drug), Metformin (Background drug)
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 894 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 46
- States / cities
- Sun City, Arizona • Tempe, Arizona • Little Rock, Arkansas + 41 more
- Conditions
- Type 2 Diabetes
- Interventions
- Degludec, Glargine, Aspart
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 180 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 4
- States / cities
- Atlanta, Georgia • New York, New York • Spokane, Washington
- Conditions
- Diabetes, Diabetes Mellitus, Type 2
- Interventions
- biphasic insulin aspart, insulin glargine
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 293 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2006
- U.S. locations
- 71
- States / cities
- Birmingham, Alabama • Tuscaloosa, Alabama • Vestavia Hills, Alabama + 59 more
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- Insulin Aspart SAR341402, Insulin Aspart, Insulin glargine U100
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 210 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 33
- States / cities
- Concord, California • Temecula, California • Ventura, California + 30 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Insulin icodec, Insulin glargine
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 984 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 97
- States / cities
- Birmingham, Alabama • Guntersville, Alabama • Little Rock, Arkansas + 85 more
- Conditions
- Type 2 Diabetes
- Interventions
- Colesevelam, Colesevelam matching placebo, Insulin glargine (Lantus)
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2008
- U.S. locations
- 1
- States / cities
- San Diego, California
- Conditions
- AMI
- Interventions
- Insulin Glargine (LANTUS), Insulin Glulisine (Apidra), Standard Therapy
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 35 Years to 80 Years
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 1
- States / cities
- Bridgewater, New Jersey
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Exenatide, Glargine Insulin
- Drug
- Lead sponsor
- Joslin Diabetes Center
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2010
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- Insulin glargine,300 U/mL, Insulin glargine (100 units /mL), Background therapy
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 463 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 13
- States / cities
- Tucson, Arizona • Atlanta, Georgia • Indianapolis, Indiana + 9 more